Substituted lactams as inhibitors of abeta protein production
US2009062256A1
LACTAMS SUBSTITUTED BY CYCLIC SUCCINATES AS INHIBITORS OF Abeta PROTEIN PRODUCTION
US2008213181A1
Preparation of Paramagnetic Nanoparticles Conjugated to Leukotriene B4 (LTB4) Receptor Antagonists, and Their Use as MRI Contrast Agents for the Detection of Infection and Inflammation
WO2007070827A2
Contrast agents for myocardium perfusion imaging
EP1951906A2
Moesin, caveolin 1 and yes associated protein 1 as predictive markers of response to dasatinib in breast cancers
WO2007056177A2
T315a and f317i mutations of bcr-abl kinase domain
ZA200606429B
Contrast agents for myocardial perfusion imaging
WO2007005491A1
Hydrazide conjugates as imaging agents
EP1809631A1
Crystalline materials of 1-(4-benzoyl-piperazin-1-yl)-2-[4-methoxy-7-(3-methyl-[1,2,4]triazol-1-yl)-1h-pyrrolo[2,3-c]pyridin-3-yl]-ethane-1,2-dione
EP1803150A1
Compounds for myocardial perfusion imaging
CN1976728A
Contrast agents for myocardial perfusion imaging.
US7344702B2
Contrast agents for myocardial perfusion imaging
CN1906198A
Processes for the preparation of pyrazolo[1,5-a]-1,3,5-triazines and intermediates thereof
US7153961B2
Salt and crystalline form thereof of a corticotropin releasing factor receptor antagonist
US7208596B2
Processes for the preparation of pyrazolo[1,5-a]-1,3,5-triazines and intermediates thereof
WO2005042033A1
Novel chemical agents comprising a cardiotonic moiety and an imaging moiety and methods of their use
WO2005044312A1
Novel chemical agents comprising an adenosine moiety or an adenosine analog moiety and an imaging moiety and methods of their use
CN1874792A
Compounds containing matrix metalloproteinase substrates and methods of their use
US7317104B2
Chelants and macrocyclic metal complex radiopharmaceuticals thereof
US2005010038A1
Chelants and macrocyclic metal complex radiopharmaceuticals thereof
